The role and efficacy of denosumab in the treatment of osteoporosis: an update

Author： Charopoulos Ioannis Orme Steve Giannoudis Peter V

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.10, Iss.2, 2011-03, pp. : 205-217

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Denosumab: A Review of its Use in the Treatment of Postmenopausal Osteoporosis

By Moen Marit D. Keam Susan J.

Drugs & Aging, Vol. 28, Iss. 1, 2011-01 ,pp. : 63-82

Adis International

Access to resources Recommend Favorite

Denosumab delivers in postmenopausal osteoporosis

Inpharma, Vol. 1, Iss. 1649, 2008-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Denosumab best value for osteoporosis in Belgium

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 606, 2010-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Denosumab bones up in postmenopausal osteoporosis

Inpharma, Vol. 1, Iss. 1527, 2006-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Amgen Canada Inc. is warning of the risk of atypical femoral fracture associated with use of the osteoporosis treatment, Prolia [denosumab].

Reactions Weekly, Vol. 1, Iss. 1430, 2012-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite